Efficacy of neoadjuvant regional arterial chemotherapy for patients with advanced gastric cancer
10.3760/cma.j.issn.1673-9752.2010.04.006
- VernacularTitle:新辅助区域动脉化疗在进展期胃癌中的临床疗效
- Author:
Yuhai BIAN
;
Fengrong YU
;
Hui CAO
;
Zhiyong SHENG
;
Xingzhi NI
;
Jie ZHUANG
;
Wei LING
;
Zhiyong WU
- Publication Type:Journal Article
- Keywords:
Gastric neoplasms;
Neoadjuvant chemotherapy;
Antineoplastic combined chemotherapy protocols;
Arterial infusion
- From:
Chinese Journal of Digestive Surgery
2010;09(4):256-258
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the efficacy and toxicity of neoadjuvant regional arterial chemotherapy in the treatment of advanced gastric cancer. Methods The clinical data of 158 patients with advanced gastric cancer and with the same clinical stages who were admitted to Renji Hospital of Shanghai Jiaotong University from February 2002 to May 2005 were retrospectively analysed. Preoperative regional arterial chemotherapy was applied to 76 patients (test group) and the remaining 82 patients only received surgical treatment (control group). The chemotherapy regimen was epirubicin (50 mg/m2) + cisplatin (60 mg/m2) + 5-fluorouracil (1000 mg/m2).This regimen was modified to oxaliplatin (130 mg/m2) + 5-fluorouracil (1000 mg/m2) since 2003, and surgery was performed 6-11 days after the chemotherapy. All patients received postoperative intravenous chemotherapy.The clinical effects, radical resection rate, operative complications and long-term survival of the two treatment methods were evaluated. All data were analysed using the chi-square test and Kaplan-Meier analysis. Results The radical resection rate was significantly higher at 86% (65/76) in the test group compared with 71% (58/82)in the control group ( x2 = 5.01, P ＜ 0. 05 ). The toxicity of the chemotherapy in the test group was mild. The postoperative complication rate was 20% (15/76) in the test group and 16% (13/82) in the control group, with no significant difference between the two groups (x2 = 0.41, P＞0.05). The median survival time was 41 months in the test group and 23 months in the control group. The 5-year overall survival rate was higher in the test group (44.6%) than that in the control group (29.1%) (x2 =3.95, P＜0. 05). Conclusions Neoadjuvant regional arterial chemotherapy is well tolerated by patients with advanced gastric cancer. It is also effective for increasing the radical resection rate and improving the long-term survival.
